Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET3 | O43151 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | FBXL19 | Q6PCT2 | 6/20 | 0.41 |
| ▸ | CXXC5 | Q7LFL8 | 6/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.41 |
| ▸ | CXXC4 | Q9H2H0 | 6/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 6/20 | 0.41 |
| ▸ | TET1 | Q8NFU7 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25809391 | 0.88 | L3MBTL3 (0.45) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL6936214 | 0.86 | JAK3 (0.39) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL20849781 | 0.84 | TET3 (0.45) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL19889017 | 0.79 | HSD11B1 (0.46) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL19971641 | 0.79 | HSD17B10 (0.42) | NAMPTHSD17B10KDM1AL3MBTL3L3MBTL1 | |
| SCHEMBL16078760 | 0.78 | USP2 (0.42) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL16122415 | 0.78 | TET3 (0.41) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL25809394 | 0.77 | TET3 (0.38) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL30367659 | 0.77 | NAMPT (0.40) | NAMPTHSD17B10KDM1AL3MBTL3L3MBTL1 | |
| SCHEMBL20669201 | 0.77 | ALDH1A1 (0.44) | KMT2ANAMPTHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388694-A | Heteroatom spiro-containing copolymer, preparation method thereof and application thereof in electrode binder | 合肥安铭盛新材料科技有限公司 | 2024-07-26 | — | — | CN | claimed |
| EP-4587435-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2025-07-23 | — | — | EP | disclosed |
| CN-118388694-A | Heteroatom spiro-containing copolymer, preparation method thereof and application thereof in electrode binder | 合肥安铭盛新材料科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024056077-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-21 | — | — | WO | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| EP-2970121-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| WO-2014151620-A1 | 5-THIAZOLECARBOXAMIDE DERVATIVES AND THEIR USE AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | TET3 3348/4885KMT2A 535/4885FBXL19 1228/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | TET3 3348/4885KMT2A 535/4885FBXL19 1228/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | TET3 3348/4885KMT2A 535/4885FBXL19 1228/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | TET3 3118/4885KMT2A 1502/4885FBXL19 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.